GLP-1 receptor agonists, the drug class that includes semaglutide (sold as Ozempic and Wegovy), appear to reduce cravings, lower overdose risk and decrease substance use disorder diagnoses in
The latter enrolled 190 patients with obesity (mean age 54.4 years, mean BMI 36.1 kg/m 2 ) and biopsy-proven MASH and moderate-to-severe fibrosis regardless of the presence of T2D, showing a BW reduction of 10.7%, 13.3%, 15.6% and 0.8% at 52 weeks with tirzepatide 5 mg, 10 mg, 15 mg and placebo, respectively 39
Do I understand that compounded GLP-1 medications are not FDA-approved finished products and have not been evaluated by the FDA for safety, quality, or efficacy
The post does not say how long such vision changes might last